Abstract:Although SARS-CoV-2 can invade the intestine, though its effect on digestion and absorption is not fully understood. In the present study, 56 COVID-19 patients and 47 age- and sex-matched healthy subjects were divided into a discovery cohort and a validation cohort. Blood, faeces and clinical information were collected from the patients in the hospital and at discharge. The faecal metabolome was analysed using gas chromatography-mass spectrometry, and Spearman's correlation analyses of clinical features, the serum metabolome, and the faecal micro- and mycobiota were conducted. The results showed that, the faeces of COVID-19 patients were enriched with important nutrients that should be metabolized or absorbed, such as sucrose and 2-palmitoyl-glycerol; diet-related components that cannot be synthesized by humans, such as 1,5-anhydroglucitol and D-pinitol; and harmful metabolites, such as oxalate, were also detected. In contrast, purine metabolites such as deoxyinosine and hypoxanthine, low-water-soluble long-chain fatty alcohols/acids such as behenic acid, compounds rarely occurring in nature such as D-allose and D-arabinose, and microbe-related compounds such as 2,4-di-tert-butylphenol were depleted in the faeces of COVID-19 patients. Moreover, these metabolites significantly correlated with altered serum metabolites such as oxalate and gut microbesincluding Ruminococcaceae, Actinomyces, Sphingomonas and Aspergillus. Although levels of several faecal metabolites, such as sucrose, 1,5-anhydroglucitol and D-pinitol, of discharged patients were not different from those of healthy controls (HCs), those of oxalate and 2-palmitoyl-glycerol did differ. Therefore, alterations in the faecal metabolome of COVID-19 patients may reflect malnutrition and intestinal inflammation and warrant greater attention. The results of present study provide new insights into the pathogenesis and treatment of COVID-19.

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential

Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Gut microbiota in COVID-19: new insights from inside

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Potential Associations Between Microbiome and COVID-19

Impact of SARS-CoV2 infection on gut microbiota dysbiosis

Gut Microbiome Alterations in COVID-19

Gut mycobiota alterations in patients with COVID-19 and H1N1 and associations with immune and gastrointestinal symptoms

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

FMT: A Potential Therapeutic and Rehabilitative Intervention for COVID-19

The Volatile and Heterogeneous Gut Microbiota Shifts of COVID‐19 Patients over the Course of a Probiotics‐assisted Therapy

Intestinal Flora As a Potential Strategy to Fight SARS-CoV-2 Infection

Coronavirus infection and gut microbiota

Integrated gut virome and bacteriome dynamics in COVID-19 patients

Traditional Chinese medicine against COVID-19: Role of the gut microbiota

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes